The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials

Published:2011-06 Issue:6 Volume:64 Page:1035-1050
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Dommasch Erica D.,Abuabara Katrina,Shin Daniel B.,Nguyen Josephine,Troxel Andrea B.,Gelfand Joel M.

Publisher

Elsevier BV

Subject

Dermatology

Reference78 articles.

1. Determinants of quality of life in patients with psoriasis: a study from the US population;Gelfand;J Am Acad Dermatol,2004

2. The risk of lymphoma in patients with psoriasis;Gelfand;J Invest Dermatol,2006

3. Risk of myocardial infarction in patients with psoriasis;Gelfand;JAMA,2006

4. The risk of mortality in patients with psoriasis: results from a population-based study;Gelfand;Arch Dermatol,2007

5. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004;Kurd;J Am Acad Dermatol,2009

Cited by 189 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biologics for Psoriasis;Dermatologic Clinics;2024-07

2. Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with targeted therapies: A meta-analysis of randomized controlled trials;Joint Bone Spine;2024-05

3. Risk of Cutaneous T Cell Lymphoma with Psoriasis Biologic Therapies;Dermatology and Therapy;2023-12-03

4. Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?—Insights from an international population‐based study;Journal of the European Academy of Dermatology and Venereology;2023-10-04

5. Tackling TNF-α in autoinflammatory disorders and autoimmune diseases: From conventional to cutting edge in biologics and RNA- based nanomedicines;Advanced Drug Delivery Reviews;2023-10